• column
  • column
    • Home
    • About Us
      • Our vision
      • Our team
      • Our founders
      • News & Resources
      • Case Studies
      • Clients
      • Advisory board
  • column
    • Our Services
      • How we work
      • Project partners
    • Preclinical Research Services
    • Clinical Trial Volunteer Opportunities
    • Clinical Trials Services
  • column
    • Contact
      • Companies
      • Volunteers
    • FOLLOW US
      • X
      • Linkedin
      • Facebook
Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations.

Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations.

by Virtus | Dec 6, 2019

Click the button below to read more about this. CLICK HERE FOR ARTICLE  ...
Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation.

Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation.

by Virtus | Dec 6, 2019

Click the button below to read more about this. CLICK HERE FOR...
Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations.

Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations.

by Virtus | Nov 6, 2019

Click the button below to read more about this. CLICK HERE FOR...
Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production.

Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production.

by Virtus | Nov 3, 2019

Click the button below to read more about this. CLICK HERE FOR...
Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation.

Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation.

by Virtus | Nov 3, 2019

Click the button below to read more about this. CLICK HERE FOR...
« Older Entries
Next Entries »

Recent Posts

  • Preclinical Efficacy Testing in Respiratory Drug Development
  • Outsourcing vs In-House Respiratory Research: Which Approach Is Right for Preclinical Drug Development?
  • Viral Challenge Preclinical Studies in Respiratory Drug Development
  • Respiratory CRO in the UK: How to Evaluate Preclinical Respiratory Research Partners
  • Asthma vs COPD Preclinical Models in Respiratory Drug Development

Recent Comments

No comments to show.

Privacy Notice and Cookie Policy





All content © 2022 Virtus Respiratory Research. All Rights Reserved.

Contact